South Korea
· Delayed Price · Currency is KRW Prestige BioPharma Company Description
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines.
The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis.
It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor.
Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
| Country | Singapore |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | So-Yeon Park |
Contact Details
Address: 21 Biopolis Road Singapore, 138567 Singapore | |
| Phone | 65 6924 6535 |
| Website | prestigebiopharma.com |
Stock Details
| Ticker Symbol | 950210 |
| Exchange | Korea Stock Exchange |
| Fiscal Year | July - June |
| Reporting Currency | KRW |
| ISIN Number | KR8702070002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| So-Yeon Park | Chief Executive Officer |
| Jinwoo Kim | Chief Financial Officer |